Ratings by H.C. Wainwright (Matt Keller)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/1/2025 | Acurx Pharmaceuticals inc. | ACXP | Maintain | Buy (Buy) |
|
Details | ||
| 9/25/2025 | FibroGen | FGEN | Maintain | Buy (Buy) |
|
Details | ||
| 9/3/2025 | FibroGen | FGEN | Maintain | Buy (Buy) |
|
Details | ||
| 8/13/2025 | Acurx Pharmaceuticals inc. | ACXP | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | FibroGen | FGEN | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2025 | Acurx Pharmaceuticals inc. | ACXP | New Coverage | Buy (N/A) |
0.37 (1.60) |
332.43% | Details | |
| 2/21/2025 | FibroGen | FGEN | Maintain | Buy (Buy) |
|
Details | ||
| 12/17/2024 | FibroGen | FGEN | New Coverage | Buy (N/A) |
0.33 (9.71) |
2842.42% | Details |
